A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Prurigo nodularis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Trevi Therapeutics
  • Most Recent Events

    • 13 Oct 2016 Results published in Trevi Therapeutics media release.
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top